Ozempic (semaglutide) eliminates the desire to eat after receiving a shot.
"with Ozempic, you get one shot, desire to eat goes away, right? You have changed a fundamental part of being human. You don't want to eat." (said at 1:12:26)
Randomized controlled trials confirm that once-weekly subcutaneous semaglutide reduces appetite, hunger, and food cravings while increasing satiety and reducing ad libitum daily energy intake by approximately 24% to 35%. However, stating that a single shot causes the desire to eat to completely go away is an overstatement of both the magnitude and onset of effect. Semaglutide suppresses and modulates appetite rather than eliminating the desire to eat entirely, and clinical treatment involves gradual dose escalation over weeks to months.
- partial: Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food pre… (Diabetes, obesity & metabolism 2017)
"After a standardised breakfast, semaglutide, compared with placebo, led to a lower ad libitum energy intake during lunch (-1255 kJ; P < .0001) and during the subsequent evening meal (P = .0401) and snacks (P = .0034), resulting in a 24% reduction in total energy intake across all ad libitum meals throughout the day (-3036 kJ; P < .0001). Fasting overall appetite suppression scores were improved with semaglutide vs placebo, while nausea ratings were similar. Semaglutide was associated with less hunger and food cravings, better control of eating and a lower preference for high-fat foods." (abstract, results)
pubmedfull study (doi) - partial: The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating… (Diabetes, obesity & metabolism 2021)
"Ad libitum energy intake was 35% lower with semaglutide versus placebo (1736 versus 2676 kJ; estimated treatment difference -940 kJ; P <0.0001). Semaglutide reduced hunger and prospective food consumption, and increased fullness and satiety when compared with placebo (all P <0.02). The CoEQ indicated better control of eating and fewer/weaker food cravings with semaglutide versus placebo (P <0.05)." (abstract, results, passage verified)
pubmedfull study (doi)